To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats.
This bill extends a federal program that provides priority review of new medical treatments for dangerous agents that pose national security threats. The legislation amends the Federal Food, Drug, and Cosmetic Act to continue the priority review voucher program for an additional ten years, pushing the expiration date from 2023 to 2033. The program encourages pharmaceutical companies to develop treatments and countermeasures for biological, chemical, radiological, and nuclear threats by offering faster FDA review of their applications. The bill affects drug manufacturers and the FDA, which will continue processing these national security-related medical countermeasures on an expedited basis. No new funding is specified in the legislation, as it simply extends an existing program's authorization period.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.